Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31177405 | 1.00 | PPARA (0.54) | PPARAPPARGKLK5GAAATM | |
| SCHEMBL31177374 | 0.90 | KLK5 (0.54) | PPARAPPARGKLK5GAAATM | |
| SCHEMBL6723017 | 0.90 | KLK5 (0.49) | PPARAPPARGKLK5ATMITGB3 | |
| SCHEMBL31177373 | 0.90 | KLK5 (0.54) | PPARAPPARGKLK5GAAATM | |
| SCHEMBL31177569 | 0.90 | KLK5 (0.54) | PPARAPPARGKLK5GAAATM | |
| SCHEMBL6723619 | 0.90 | PPARA (0.52) | PPARAPPARGKLK5ATMITGB3 | |
| SCHEMBL15775826 | 0.89 | KLK5 (0.61) | PPARAPPARGKLK5ATMCTSS | |
| SCHEMBL5650822 | 0.89 | KLK5 (0.61) | PPARAPPARGKLK5ATMCTSS | |
| SCHEMBL7356486 | 0.89 | KLK5 (0.61) | PPARAPPARGKLK5ATMCTSS | |
| SCHEMBL288838 | 0.89 | KLK5 (0.61) | PPARAPPARGKLK5ATMCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673772-B2 | INHIBITING THE ENZYMATIC ACTIVITY OF HIV PROTEASE | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-01-06 | — | — | US | disclosed |
| US-20020049165-A1 | Novel dipeptide compounds and their use as medicines | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2002-04-25 | — | — | US | disclosed |
| EP-1157997-A1 | NOVEL DIPEPTIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN ENERGY CORPORATION (JP) | 2001-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049165-A1 | Novel dipeptide compounds and their use as medicines | DNPEP, PEPD, ANPEP | PPARA 3639/4885PPARG 4190/4885KLK5 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.